AxoGen (AXGN) to Release Quarterly Earnings on Thursday

AxoGen (NASDAQ:AXGN) is anticipated to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $48.35 million for the quarter.

AxoGen Trading Up 2.0 %

AXGN opened at $16.51 on Wednesday. AxoGen has a twelve month low of $5.55 and a twelve month high of $21.00. The company has a fifty day moving average of $17.34 and a 200-day moving average of $16.21. The stock has a market cap of $732.12 million, a PE ratio of -51.59 and a beta of 1.00. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67.

Insider Activity

In related news, insider Erick Wayne Devinney sold 15,111 shares of the business’s stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the transaction, the insider now directly owns 217,762 shares of the company’s stock, valued at approximately $3,810,835. The trade was a 6.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Amy Mcbride Wendell sold 5,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the transaction, the director now owns 97,899 shares of the company’s stock, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on AXGN. Canaccord Genuity Group lifted their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Lake Street Capital began coverage on shares of AxoGen in a research report on Monday, March 17th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 target price on shares of AxoGen in a research report on Wednesday, March 5th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $22.60.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.